Amycretin: The Dual GLP-1 & Amylin Agonist Redefining Weight Loss Research (2026)

Among the most talked-about compounds in obesity and metabolic research right now, amycretin stands out for a deceptively simple reason: it does what no single approved therapy has done before — it simultaneously activates both the GLP-1 receptor and the amylin receptor using a single, unimolecular construct. Early clinical data suggest weight loss figures that outpace semaglutide and rival the best triple-agonist candidates in the pipeline. This guide breaks down the science, the trial data, the safety profile, and everything a researcher needs to understand about amycretin in 2026.

What Is Amycretin? Mechanism of Action Explained

Amycretin is a novel, synthetic peptide developed by Novo Nordisk. Its structure comprises two covalently linked peptide moieties: one that acts as a GLP-1 receptor agonist (analogous to the active component in semaglutide) and one that acts as an amylin receptor agonist (analogous to pramlintide, a synthetic amylin analog). These two moieties are joined at the molecular level, meaning the body receives both signals from a single injection or dose — not from two separate drugs.

This matters because GLP-1 and amylin act through complementary but distinct pathways:

• GLP-1 receptor activation slows gastric emptying, enhances insulin secretion in a glucose-dependent manner, suppresses glucagon, and signals satiety in the hypothalamus.
• Amylin receptor activation reduces food intake via area postrema signaling in the brainstem, independently of the hypothalamic GLP-1 pathway. Amylin also slows gastric emptying and suppresses post-meal glucagon.

By combining both mechanisms, amycretin achieves a synergistic appetite-suppression effect. Preclinical studies in rodent models demonstrated that the combination produced significantly greater reductions in body weight and food intake than either mechanism alone at matched doses. This complementary neurological targeting — hypothalamus plus brainstem — is the core scientific rationale for the compound.

Amycretin Clinical Trial Results: What the Data Show

Two major clinical data sets have been published or presented as of 2026, covering both the oral and subcutaneous formulations.

Phase 1b/2a Subcutaneous Trial (The Lancet, 2024)

This randomized, placebo-controlled trial enrolled adults with overweight or obesity (BMI ≥27 kg/m²) without diabetes. Participants received once-weekly subcutaneous amycretin at doses ranging from 1.5 mg to 60 mg over 36 weeks.

Key efficacy findings:

• At the highest dose (60 mg/week), participants lost an average of approximately 22% of body weight over 36 weeks.
• Even at lower doses, weight loss consistently exceeded placebo by a clinically meaningful margin.
• Reductions in waist circumference, blood pressure, and fasting glucose were also observed across dose groups.
• The weight loss trajectory continued to trend downward at the end of the trial period, suggesting the plateau had not yet been reached.

For context, semaglutide 2.4 mg achieves roughly 15% weight loss at 68 weeks in the STEP trials, and tirzepatide (a dual GIP/GLP-1 agonist) achieves approximately 20–22% at 72 weeks. Amycretin reaching similar figures at 36 weeks — a shorter trial window — is a significant headline finding.

Oral Amycretin Phase 1 Trial (ACC 2025 Presentation)

A separate Phase 1 trial evaluated an oral formulation of amycretin containing salcaprozate sodium (SNAC) as an absorption enhancer — the same technology used in oral semaglutide (Rybelsus). Over 12 weeks, oral amycretin produced approximately 13.1% placebo-adjusted weight loss in participants with overweight or obesity. This outperforms oral semaglutide at comparable timepoints and represents a potentially transformative oral obesity therapy if confirmed in larger trials.

Amycretin Safety Profile and Side Effects

Across both the subcutaneous and oral Phase 1 trials, amycretin's safety and tolerability profile was described as consistent with GLP-1 receptor agonist class effects. No unexpected or novel safety signals emerged at any dose studied.

The most commonly reported adverse events included:

• Nausea — the most frequent complaint, particularly during dose escalation phases. Severity was generally mild to moderate.
• Vomiting — reported more often at higher doses but manageable with standard antiemetic protocols in the trial setting.
• Decreased appetite — while technically a desired pharmacological effect, this was also coded as an adverse event in some participants.
• Diarrhea and constipation — consistent with GI motility changes expected from gastric emptying modulation.
• Injection site reactions — mild and transient in the subcutaneous arm.

Importantly, no serious cardiovascular adverse events were attributed to the compound. Heart rate increases — a known class effect of GLP-1 agonists — were observed but within expected ranges. No cases of pancreatitis or thyroid C-cell tumors were reported, though the trial durations are not sufficient to draw long-term conclusions on rare events.

The oral formulation had a comparable adverse event profile to the subcutaneous version, with GI symptoms predominating during the initial weeks. Notably, the American College of Cardiology presentation in 2025 concluded that both oral and subcutaneous amycretin were similarly safe and tolerated compared to GLP-1 monoagonists, with no new class-specific concerns from the amylin agonist component.

Amycretin vs. Other Research Peptides for Metabolic Research

Researchers evaluating amycretin within the broader landscape of incretin-based metabolic compounds should understand where it fits relative to established and emerging research peptides.

Amycretin vs. Semaglutide

Semaglutide is a GLP-1 receptor monoagonist — it activates only the GLP-1 pathway. Amycretin adds the amylin receptor component, engaging a second, complementary satiety circuit. The net result in early trials is meaningfully greater weight loss over a shorter timeframe. Both compounds have similar GI side effect profiles.

Amycretin vs. Retatrutide

Retatrutide is a triple agonist targeting GLP-1, GIP, and glucagon receptors. It represents a different strategy — adding glucagon receptor activity to increase energy expenditure rather than adding amylin-pathway satiety signaling. Early Phase 2 retatrutide data also showed impressive weight loss (~24% at 48 weeks), placing both compounds in a similar efficacy tier, though through distinct mechanisms.

Amycretin vs. CJC-1295 / Ipamorelin

CJC-1295 and ipamorelin are growth hormone secretagogues — they work by stimulating GH release, not by modulating appetite or incretin pathways. These compounds are primarily researched for body composition, recovery, and anti-aging applications rather than primary obesity treatment. They occupy an entirely different mechanistic category from amycretin.

Key Considerations for Amycretin Research

For researchers tracking amycretin's development trajectory, several important points bear emphasis:

1. Still in clinical development: As of 2026, amycretin has completed Phase 1b/2a trials and is not approved by the FDA, EMA, or any major regulatory authority for any indication. It is strictly a research-stage compound.

2. Dose-response relationship is being refined: The Phase 1b/2a trial explored doses from 1.5 mg to 60 mg weekly. The 60 mg dose showed the greatest efficacy but also the highest incidence of GI side effects. The optimal therapeutic dose — balancing efficacy and tolerability — has not yet been determined for Phase 3 purposes.

3. Oral bioavailability is a major differentiator: If Phase 2/3 data confirm the Phase 1 oral efficacy signal, an oral formulation producing ~13% weight loss in 12 weeks would represent a significant advance over any currently approved oral obesity therapy. This is a key differentiating factor relative to injectable-only competitors.

4. Long-term cardiovascular outcome data are pending: Like all novel obesity agents, amycretin will require dedicated cardiovascular outcome trials (CVOTs) before regulatory approval. None have been initiated or completed as of 2026.

5. Molecular stability considerations: Joining two peptide moieties covalently is a complex pharmaceutical engineering challenge. The stability, immunogenicity, and manufacturing scalability of the amycretin molecule at commercial scale remain topics of ongoing research and development.

Frequently Asked Questions About Amycretin

Amycretin Research Summary: The Bottom Line

Amycretin represents one of the most scientifically compelling metabolic research compounds in the current pipeline. Its unimolecular dual agonism — combining GLP-1 and amylin receptor activity in a single peptide construct — offers a mechanistically sound rationale for superior weight loss relative to GLP-1 monotherapy, and early Phase 1b/2a data have largely validated that hypothesis. Weight reductions approaching 22% at 36 weeks, combined with a safety profile consistent with well-established GLP-1 receptor agonist class effects, place amycretin firmly at the forefront of next-generation obesity research.

The oral formulation data are particularly noteworthy: if confirmed at scale, an oral pill achieving double-digit weight loss would reshape the therapeutic landscape for obesity management. Researchers and clinicians tracking incretin-based therapies should monitor Novo Nordisk's Phase 2 and forthcoming Phase 3 trial results closely.

For researchers interested in the broader landscape of peptide-based metabolic and weight-loss compounds, related compounds worth reviewing include semaglutide, retatrutide, and growth hormone secretagogues such as ipamorelin and CJC-1295.